The erythropoietin neuroprotective effect: Assessment in cabg surgery (tenpeaks): A randomized, double-blind, placebo controlled, proof-of-concept clinical trial

Stroke

Volumn 40, Issue 8, 2009, Pages 2769-2775

  Haljan, Gregory ^a   Maitland, Andrew ^a   Buchan, Alastair ^d   Arora, Rakesh C ^c   King, Michael ^b   Haigh, John ^a   Culleton, Bruce ^a   Faris, Peter ^a   Zygun, David ^a,e  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e FOOTHILLS HOSPITAL   (Canada)

Author keywords

Coronary artery bypass; Neuroprotective agents; Recombinant erythropoietin

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ATTENTION; BRAIN PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; FOLLOW UP; HUMAN; MALE; MOTOR PERFORMANCE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERBAL MEMORY; VISUAL MEMORY; VISUOMOTOR COORDINATION;

AGED; COGNITION DISORDERS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; ERYTHROPOIETIN, RECOMBINANT; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; POSTOPERATIVE COMPLICATIONS;

EID: 68749108372     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.549436     Document Type: Article

References (41)

1. Sibbald B. Declining CABG rate means fewer jobs for surgeons. CMAJ. 2005;173:583-584.
2. Newman MF, Mathew JP, Grocott HP, Mackensen GB, Monk T, Welsh-Bohmer KA, Blumenthal JA, Laskowitz DT, Mark DB. Central nervous system injury associated with cardiac surgery. Lancet. 2006;368: 694-703.
3. Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA, Neurological Outcome Research G, the Cardiothoracic Anesthesiology Research Endeavors I. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med. 2001;344:395-402.
4. [see comment][erratum appears in N Engl J Med. 2001;344:1876].
5. Newman MF, Grocott HP, Mathew JP, White WD, Landolfo K, Reves JG, Laskowitz DT, Mark DB, Blumenthal JA, Neurologic Outcome Research G, the Cardiothoracic Anesthesia Research Endeavors Investigators of the Duke Heart C. Report of the substudy assessing the impact of neurocognitive function on quality of life 5 years after cardiac surgery. Stroke. 2001;32:2874-2881.
6. Puskas JD, Winston AD, Wright CE, Gott JP, Brown WM III, Craver JM, Jones EL, Guyton RA, Weintraub WS. Stroke after coronary artery operation: incidence, correlates, outcome, and cost. Ann Thorac Surg. 2000;69:1053-1056.
7. Cazzola M, Mercuriali F, Brugnara C. Use of Recombinant Human Erythropoietin Outside the Setting of Uremia. Blood. 1997;89: 4248-4267.
8. Siren AL, Ehrenreich H. Erythropoietin - a novel concept for neuroprotection. Eur Arch Psych Clin Neurosci. 2001;251:179-184.
9. Ehrenreich H, Siren AL. Neuroprotection-what does it mean?-What means do we have? Eur Arch Psych Clin Neurosci. 2001;251:149-151.
10. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493.
11. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience. 1997;76:105-116.
12. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, Sasaki R. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Comm. 1998;253:26-32.
13. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001;98:4044-4049.
14. Bernaudin M, Nedelec AS, Divoux D, MacKenzie ET, Petit E, Schumann-Bard P. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metabol. 2002;22: 393-403.
15. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000;97:10526-10531.
16. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.
17. O'Shaughnessy JA, Vukelja SJ, Holmes FA, Savin M, Jones M, Royall D, George M, Von Hoff D. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer. 2005;5:439-446.
18. Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, Nissenson AR. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int. 1991;39:155-163.
19. Nissenson AR. Epoetin and cognitive function. Am J Kidney Dis. 1992;20:21-24.
20. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function. [see comment]. Am J Kidney Dis. 1999;33:1122-1130.
21. Murkin JM, Newman SP, Stump DA, Blumenthal JA. Statement of consensus on assessment of neurobehavioral outcomes after cardiac surgery. Ann Thorac Surg. 1995;59:1289-1295.
22. Mahanna EP, Blumenthal JA, White WD, Croughwell ND, Clancy CP, Smith LR, Newman MF. Defining neuropsychological dysfunction after coronary artery bypass grafting. Ann Thorac Surg. 1996;61:1342-1347.
23. Roach GW, Kanchuger M, Mangano CM, Newman M, Nussmeier N, Wolman R, Aggarwal A, Marschall K, Graham SH, Ley C. Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators. [see comment]. N Engl J Med. 1996;335:1857-1863.
24. Blauth CI. Macroemboli and microemboli during cardiopulmonary bypass. Ann Thorac Surg. 1995;59:1300-1303.
25. Bar-Yosef S, Anders M, Mackensen GB, Ti LK, Mathew JP, Phillips-Bute B, Messier RH, Grocott HP, Neurological Outcome Research G, Center CIot DH. Aortic atheroma burden and cognitive dysfunction after coronary artery bypass graft surgery. Ann Thorac Surg. 2004;78:1556-1562.
26. Fearn SJ, Pole R, Wesnes K, Faragher EB, Hooper TL, McCollum CN. Cerebral injury during cardiopulmonary bypass: emboli impair memory. J Thorac Cardiovasc Surg. 2001;121:1150-1160.
27. Moody DM, Brown WR, Challa VR, Stump DA, Reboussin DM, Legault C. Brain microemboli associated with cardiopulmonary bypass: a histologic and magnetic resonance imaging study. Ann Thorac Surg. 1995;59:1304-1307.
28. Selnes OA, McKhann GM. Neurocognitive complications after coronary artery bypass surgery. Ann Neurol. 2005;57:615-621.
29. Aebert H, Kirchner S, Keyser A, Birnbaum DE, Holler E, Andreesen R, Eissner G. Endothelial apoptosis is induced by serum of patients after cardiopulmonary bypass. Eur J Cardio Thorac Surg. 2000;18:589-593.
30. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem. 2001;276:39469-39475.
31. Biesma DH, Bronkhorst PJ, de Groot PG, van de Wiel A, Kraaijenhagen RJ, Marx JJ. The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors. J Lab Clin Med. 1994;124:42-47.
32. Sowade O, Ziemer S, Sowade B, Franke W, Messinger D, Ziebell E, Scigalla P, Warnke H. The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery. J Lab Clin Med. 1997;129:376-383.
33. Laupacis A, Fergusson D. Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Transfus Med. 1998;8:309-317.
34. Sowade B, Sowade O, Mocks J, Franke W, Warnke H. The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med. 1998;1:303-314.
35. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T, Group EPOCCT. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002;288:2827-2835.
36. Brower V Erythropoietin may impair, not improve, cancer survival. Nat Med. 2003;9.
37. Leyland-Jones B, Investigators B, Study G. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459-460.
38. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403-1408.
39. Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67:2346-2353.
40. Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotech. 2006;24:613-614.
41. Sharma B, Ryan MH, Boven K. Reactions to Eprex's adverse reactions. Nat Biotech. 2006;24:1199-1200.